The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hepatitis B Antiviral Drugs Market Research Report 2024
Synopsis
Global Hepatitis B Antiviral Drugs market is projected to reach US$ million in 2030, increasing from US$ million in 2023, with the CAGR of % during the period of 2024 to 2030.
Key companies engaged in the Hepatitis B Antiviral Drugs industry include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical and Hansoh Pharmaceutical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2023.
When refers to consumption region, % value of Hepatitis B Antiviral Drugs were sold to North America, Europe and Asia Pacific in 2023. Moreover, China, plays a key role in the whole Hepatitis B Antiviral Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2019-2023) and forecast calculation (2024-2030), aims to help readers to get a comprehensive understanding of global Hepatitis B Antiviral Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Nucleos(t)ide Analogues
Interferons
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hepatitis B Antiviral Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Global Hepatitis B Antiviral Drugs market is projected to reach US$ million in 2030, increasing from US$ million in 2023, with the CAGR of % during the period of 2024 to 2030.
Key companies engaged in the Hepatitis B Antiviral Drugs industry include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical and Hansoh Pharmaceutical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2023.
When refers to consumption region, % value of Hepatitis B Antiviral Drugs were sold to North America, Europe and Asia Pacific in 2023. Moreover, China, plays a key role in the whole Hepatitis B Antiviral Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2019-2023) and forecast calculation (2024-2030), aims to help readers to get a comprehensive understanding of global Hepatitis B Antiviral Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Nucleos(t)ide Analogues
Interferons
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hepatitis B Antiviral Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatitis B Antiviral Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Nucleos(t)ide Analogues
1.2.3 Interferons
1.3 Market by Application
1.3.1 Global Hepatitis B Antiviral Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatitis B Antiviral Drugs Market Perspective (2019-2030)
2.2 Hepatitis B Antiviral Drugs Growth Trends by Region
2.2.1 Global Hepatitis B Antiviral Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hepatitis B Antiviral Drugs Historic Market Size by Region (2019-2024)
2.2.3 Hepatitis B Antiviral Drugs Forecasted Market Size by Region (2025-2030)
2.3 Hepatitis B Antiviral Drugs Market Dynamics
2.3.1 Hepatitis B Antiviral Drugs Industry Trends
2.3.2 Hepatitis B Antiviral Drugs Market Drivers
2.3.3 Hepatitis B Antiviral Drugs Market Challenges
2.3.4 Hepatitis B Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatitis B Antiviral Drugs Players by Revenue
3.1.1 Global Top Hepatitis B Antiviral Drugs Players by Revenue (2019-2024)
3.1.2 Global Hepatitis B Antiviral Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Hepatitis B Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hepatitis B Antiviral Drugs Revenue
3.4 Global Hepatitis B Antiviral Drugs Market Concentration Ratio
3.4.1 Global Hepatitis B Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatitis B Antiviral Drugs Revenue in 2023
3.5 Hepatitis B Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Hepatitis B Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Hepatitis B Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hepatitis B Antiviral Drugs Breakdown Data by Type
4.1 Global Hepatitis B Antiviral Drugs Historic Market Size by Type (2019-2024)
4.2 Global Hepatitis B Antiviral Drugs Forecasted Market Size by Type (2025-2030)
5 Hepatitis B Antiviral Drugs Breakdown Data by Application
5.1 Global Hepatitis B Antiviral Drugs Historic Market Size by Application (2019-2024)
5.2 Global Hepatitis B Antiviral Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hepatitis B Antiviral Drugs Market Size (2019-2030)
6.2 North America Hepatitis B Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hepatitis B Antiviral Drugs Market Size by Country (2019-2024)
6.4 North America Hepatitis B Antiviral Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hepatitis B Antiviral Drugs Market Size (2019-2030)
7.2 Europe Hepatitis B Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hepatitis B Antiviral Drugs Market Size by Country (2019-2024)
7.4 Europe Hepatitis B Antiviral Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hepatitis B Antiviral Drugs Market Size (2019-2030)
8.2 Asia-Pacific Hepatitis B Antiviral Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hepatitis B Antiviral Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Hepatitis B Antiviral Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hepatitis B Antiviral Drugs Market Size (2019-2030)
9.2 Latin America Hepatitis B Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hepatitis B Antiviral Drugs Market Size by Country (2019-2024)
9.4 Latin America Hepatitis B Antiviral Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatitis B Antiviral Drugs Market Size (2019-2030)
10.2 Middle East & Africa Hepatitis B Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hepatitis B Antiviral Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Hepatitis B Antiviral Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Hepatitis B Antiviral Drugs Introduction
11.1.4 GSK Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Detail
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Hepatitis B Antiviral Drugs Introduction
11.2.4 Bristol Myers Squibb Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Detail
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Hepatitis B Antiviral Drugs Introduction
11.3.4 Gilead Sciences Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.3.5 Gilead Sciences Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Hepatitis B Antiviral Drugs Introduction
11.4.4 Novartis Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Hepatitis B Antiviral Drugs Introduction
11.5.4 Roche Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Hepatitis B Antiviral Drugs Introduction
11.6.4 Merck Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Hepatitis B Antiviral Drugs Introduction
11.7.4 Johnson & Johnson Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 Dawnrays Pharmaceutical
11.8.1 Dawnrays Pharmaceutical Company Detail
11.8.2 Dawnrays Pharmaceutical Business Overview
11.8.3 Dawnrays Pharmaceutical Hepatitis B Antiviral Drugs Introduction
11.8.4 Dawnrays Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.8.5 Dawnrays Pharmaceutical Recent Development
11.9 Hansoh Pharmaceutical
11.9.1 Hansoh Pharmaceutical Company Detail
11.9.2 Hansoh Pharmaceutical Business Overview
11.9.3 Hansoh Pharmaceutical Hepatitis B Antiviral Drugs Introduction
11.9.4 Hansoh Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.9.5 Hansoh Pharmaceutical Recent Development
11.10 Chia Tai-Tianqing Pharmaceutical
11.10.1 Chia Tai-Tianqing Pharmaceutical Company Detail
11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview
11.10.3 Chia Tai-Tianqing Pharmaceutical Hepatitis B Antiviral Drugs Introduction
11.10.4 Chia Tai-Tianqing Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.10.5 Chia Tai-Tianqing Pharmaceutical Recent Development
11.11 Qilu pharmaceutical
11.11.1 Qilu pharmaceutical Company Detail
11.11.2 Qilu pharmaceutical Business Overview
11.11.3 Qilu pharmaceutical Hepatitis B Antiviral Drugs Introduction
11.11.4 Qilu pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.11.5 Qilu pharmaceutical Recent Development
11.12 Fujian Cosunter Pharma
11.12.1 Fujian Cosunter Pharma Company Detail
11.12.2 Fujian Cosunter Pharma Business Overview
11.12.3 Fujian Cosunter Pharma Hepatitis B Antiviral Drugs Introduction
11.12.4 Fujian Cosunter Pharma Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.12.5 Fujian Cosunter Pharma Recent Development
11.13 Xiamen Amoytop Biotech
11.13.1 Xiamen Amoytop Biotech Company Detail
11.13.2 Xiamen Amoytop Biotech Business Overview
11.13.3 Xiamen Amoytop Biotech Hepatitis B Antiviral Drugs Introduction
11.13.4 Xiamen Amoytop Biotech Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.13.5 Xiamen Amoytop Biotech Recent Development
11.14 YaoPharma
11.14.1 YaoPharma Company Detail
11.14.2 YaoPharma Business Overview
11.14.3 YaoPharma Hepatitis B Antiviral Drugs Introduction
11.14.4 YaoPharma Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.14.5 YaoPharma Recent Development
11.15 Kelun Pharmaceutical
11.15.1 Kelun Pharmaceutical Company Detail
11.15.2 Kelun Pharmaceutical Business Overview
11.15.3 Kelun Pharmaceutical Hepatitis B Antiviral Drugs Introduction
11.15.4 Kelun Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2019-2024)
11.15.5 Kelun Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
